ATE452196T1 - Immuntoxin-fusionsproteine und mittel zu deren expression - Google Patents

Immuntoxin-fusionsproteine und mittel zu deren expression

Info

Publication number
ATE452196T1
ATE452196T1 AT01935689T AT01935689T ATE452196T1 AT E452196 T1 ATE452196 T1 AT E452196T1 AT 01935689 T AT01935689 T AT 01935689T AT 01935689 T AT01935689 T AT 01935689T AT E452196 T1 ATE452196 T1 AT E452196T1
Authority
AT
Austria
Prior art keywords
fusion proteins
immuntoxin
expressing
agent
abstract
Prior art date
Application number
AT01935689T
Other languages
English (en)
Inventor
David Neville
Jerry Thompson
Huaizhong Hu
Jung-Hee Woo
Shenglin Ma
Jonathan Hexham
Mary Digan
Original Assignee
Us Gov Health & Human Serv
Novartis Erfind Verwalt Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Novartis Erfind Verwalt Gmbh filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE452196T1 publication Critical patent/ATE452196T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01935689T 2000-05-18 2001-05-18 Immuntoxin-fusionsproteine und mittel zu deren expression ATE452196T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57379700A 2000-05-18 2000-05-18
PCT/US2001/016125 WO2001087982A2 (en) 2000-05-18 2001-05-18 Immunotoxin fusion proteins and means for expression thereof

Publications (1)

Publication Number Publication Date
ATE452196T1 true ATE452196T1 (de) 2010-01-15

Family

ID=24293426

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01935689T ATE452196T1 (de) 2000-05-18 2001-05-18 Immuntoxin-fusionsproteine und mittel zu deren expression

Country Status (8)

Country Link
EP (1) EP1287147B1 (de)
JP (1) JP4927291B2 (de)
AT (1) ATE452196T1 (de)
AU (2) AU2001261760B2 (de)
CA (2) CA2409746C (de)
DE (1) DE60140802D1 (de)
HK (1) HK1054763B (de)
WO (1) WO2001087982A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0128510D0 (en) * 2001-11-28 2002-01-23 Novartis Ag Organic compounds
AU2002361390A1 (en) * 2001-12-14 2003-06-30 Friedrich-Alexander-Universitaet Erlangen-Nuernberg Anti-cd7 immunotoxin as fusion protein
ES2559763T3 (es) 2002-09-10 2016-02-15 Affimed Gmbh Anticuerpo humano específico de CD3 con propiedades inmunosupresoras
AU2004262023B2 (en) * 2003-08-01 2011-03-10 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health Methods for expression and purification of immunotoxins
CA2617877A1 (en) * 2005-08-02 2007-04-19 Planet Biotechnology, Inc. Improved chimeric toxin receptor proteins and chimeric toxin receptor proteins for treatment and prevention of anthrax
FR2897069B1 (fr) 2006-02-08 2012-06-08 Centre Nat Rech Scient Construction de nouveaux variants de l'enzyme dextrane-saccharase dsr-s par ingienerie moleculaire.
WO2009017823A2 (en) * 2007-08-01 2009-02-05 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health Of Human Services, National Institutes Of Health A fold-back diabody diphtheria toxin immunotoxin and methods of use
DK2215247T3 (en) * 2007-11-13 2014-12-08 Scripps Research Inst Preparation of a fusion of cytotoxic antibody toxin into eukaryotic algae
US9321820B2 (en) * 2009-10-14 2016-04-26 The Regents Of The University Of Colorado Compositions and methods for treating bladder cancer
WO2013156054A1 (en) 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
CN103173429A (zh) * 2013-03-11 2013-06-26 江南大学 一种热稳定性提高的重组胰蛋白酶
GB201607979D0 (en) 2016-05-06 2016-06-22 Liverpool School Tropical Medicine Monomeric proteins and uses thereof
EP3496707A4 (de) * 2016-08-09 2020-03-25 Angimmune, LLC Behandlung von krebs unter verwendung einer kombination aus immunmodulation und checkpoint-inhibitoren
WO2019149219A1 (zh) * 2018-02-05 2019-08-08 思路迪（北京）医药科技有限公司 抗-cd3免疫毒素联合抗-pd-l1单域抗体治疗癌症的应用
US12268714B2 (en) 2018-09-14 2025-04-08 Luca Science Inc. Transplantation of mitochondria into lymphoid organ and composition therefor
WO2020260368A1 (en) 2019-06-24 2020-12-30 Universität Stuttgart Tnfr2 agonists with improved stability
EP4106812A4 (de) * 2020-02-18 2024-02-21 The Regents of the University of Colorado, a Body Corporate Zusammensetzungen und verfahren zur induzierung von immuntoleranz bei transplantationsempfängern

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5663796A (en) * 1995-04-14 1996-10-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods of inducing immune tolerance using immunotoxins
US6632928B1 (en) * 1997-03-05 2003-10-14 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxins and methods of inducing immune tolerance
CA2283497A1 (en) * 1997-03-05 1998-09-11 David M. Neville Vectors and methods for expression of mutant proteins

Also Published As

Publication number Publication date
WO2001087982A2 (en) 2001-11-22
DE60140802D1 (de) 2010-01-28
EP1287147A2 (de) 2003-03-05
JP4927291B2 (ja) 2012-05-09
JP2003533219A (ja) 2003-11-11
CA2858692A1 (en) 2001-11-22
AU6176001A (en) 2001-11-26
EP1287147B1 (de) 2009-12-16
CA2409746C (en) 2014-11-25
HK1054763B (en) 2010-10-22
CA2409746A1 (en) 2001-11-22
WO2001087982A3 (en) 2002-03-21
AU2001261760B2 (en) 2007-03-29
HK1054763A1 (en) 2003-12-12

Similar Documents

Publication Publication Date Title
DE60140802D1 (de) Immuntoxin-fusionsproteine und mittel zu deren expression
MXPA04005266A (es) Inmunocitocinas con selectividad modulada.
ATE544776T1 (de) Chimäre dna-bindeproteine
WO2001049728A3 (en) HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
AU2003234323A1 (en) Fast electrical lysis of cells and rapid collection of the contents thereof using capillary electrophoresis
DE60144145D1 (de) Subtilisin-variante
WO2004063362A3 (en) Cell cycle progression proteins
DK1088084T3 (da) Erythropoietin analog-humant serumalbumin fusionsprotein
BG101103A (bg) Теломераза при бозайници
ATE349540T1 (de) Expression der bazillus thuringiensis cry- proteine in pflanzen-plastiden
DE69916807D1 (de) Kostimulatorische blockade und gemischter chimerismus in allotransplantationen
IT1295976B1 (it) Fermentatore da utilizzare, in particolare, nella industria enologica
IL136668A0 (en) Restin and methods of use thereof
ATE296312T1 (de) Metalkomplexbildner
EP4670724A3 (de) Monoklonale anti-gprc5d-antikörper und verwendungen davon
EP1355654A4 (de) "in niederen alkoholen unlöslicher extrakt von hovenia dulcis var, koreana nakai, hieraus isoliertes polysaccharid sowie dieses enthaltende antihepatotoxische zusammensetzung"
NO971059L (no) Modifiserte human-C3-proteiner
AU3365499A (en) Isolated multimeric complexes useful in analysis of t cells, peptides useful in making the complexes, and uses thereof
ATE256392T1 (de) Verwendung von polyaminosäurederivate als konservierungsmittel
WO2003098661A3 (en) Chemical and biological hazard sensor system and methods thereof
DE60234496D1 (de) Virusvektor zur gentherapie
DE69714451D1 (de) Prionbindende proteine und deren verwendungen
WO2001002563A3 (en) HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS
ES2194237T3 (es) Preparaciones cosmeticas.
WO2003045429A3 (en) Anti-t cell immunotoxin fusion protein and its therapeutic use

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties